Rigel Pharmaceuticals
RIGL
120 hedge funds and large institutions have $168M invested in Rigel Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 49 increasing their positions, 30 reducing their positions, and 12 closing their positions.
63% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 30
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1% less funds holding
Funds holding: 121 → 120 (-1)
8% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 12
32% less capital invested
Capital invested by funds: $248M → $168M (-$79.7M)
Top Buyers
| 1 |
SCM
Sio Capital Management
New York
|
+$3.99M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.67M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$2.59M |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$1.89M |
| 5 |
PC
Paulson & Co
New York
|
+$1.16M |
Top Sellers
| 1 |
BC
Broadfin Capital
New York
|
-$9.47M |
| 2 |
Axa
Paris,
France
|
-$5.86M |
| 3 |
UBS AM
Chicago,
Illinois
|
-$4.12M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.42M |
| 5 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$952K |
RIGL Hedge Fund Activity: Q1 2016 in Review
120 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q1 2016, worth a combined $168M — down 32% from $248M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of RIGL and 11 opened new positions — a net loss of 1 holder — while 30 trimmed existing stakes and 49 added.
The largest buyer was Sio Capital Management, opening a new position worth an estimated $3.99M. The largest seller was Broadfin Capital, exiting entirely with an estimated $9.47M sold.
- 120 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q1 2016, down from 121 in Q4 2015.
- Funds reported $168M of Rigel Pharmaceuticals stock for Q1 2016, down 32% quarter-over-quarter.
- 11 funds opened new Rigel Pharmaceuticals positions in Q1 2016 and 12 closed out, a net change of -1 holder.
- The largest Rigel Pharmaceuticals buyer in Q1 2016 was Sio Capital Management, an estimated $3.99M added.
- The largest Rigel Pharmaceuticals seller in Q1 2016 was Broadfin Capital, an estimated $9.47M sold.
Based on aggregated 13F filings for Q1 2016.